|
DXS International PLC on Thursday said it expects a ‘modest’ revenue decline, but to have turned a profit nonetheless, for its latest year. The Leicestershire, England-based healthcare information and clinical decision support systems provider said it expects to report its results, for the year ended April 30, on or before September 18. DXS expects turnover for the year to be ‘marginally lower’ than that of the previous year, with revenue totalling approximately £3.4 million. It said this is mainly due to less R&D tax credit income being recognised during the period. However, DXS said that despite the ‘modest reduction in revenue,’ it expects to report ‘a small profit’ for financial 2026. This would represent ‘a meaningful improvement’ from its loss of around £90,000 for financial 2025. ‘This reflects continued operational discipline and management focus on efficiency and cost control,’ the company stated. DXS also said its balance sheet has strengthened, and that it has made encouraging progress with its new NexGen referral solution, with ‘highly positive’ outcomes in customer trials and 10 pilot deployments active as of June 30. Furthermore, DXS believes that the UK National Health Service’s restructuring, with its 42 integrated care boards expected to merge into 28 organisations, ‘presents a significant long-term opportunity’. ‘As ICBs merge, a growing number will comprise GP practices that already utilise the DXS SMART Referral solution...This creates a natural opportunity for standardisation across larger healthcare economies, potentially increasing adoption of the DXS SMART Referral solution and supporting future recurring revenue growth,’ it explained. DXS also expects its central funding agreement with the NHS to be renewed, following recent delays, by September 2027. The latter extended its existing agreements until that time. ‘Overall, while revenue growth has progressed at a slower pace than the board would have liked...The company continues to see strong potential across its product portfolio and believes the foundations established over the last year position it well for sustainable future growth,’ DXS said. ‘Whilst market conditions and external NHS funding delays have impacted the pace of growth, we are encouraged by the progress made across the business,’ commented Chief Executive Officer David Immelman. ‘Delivering profitability, strengthening the balance sheet, and seeing positive customer engagement with our NexGen referral platform are all important milestones.’ DXS shares rose 8.0% to 1.35 pence in London on Thursday. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
